Sign in

CIK 0001826457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Monte Rosa Therapeutics, Inc.

Sign in to watch
Ticker
GLUE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
617-949-2643
Business address
321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
Former names
Monte Rosa Therapeutics, Inc.
  1. 4 Open-market sale Chief Scientific Officer sold 3,155 shares at $15.17 ($47,861)
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Open-market sale Principal Accounting Officer sold 2,062 shares at $4.45 ($9,174)
  10. 4 Open-market buy Director bought 10,000 shares at $5.84 ($58,383)
  11. 4 Grant or award Chief Business & Legal Officer acquired 36,000 shares (grant or award)
  12. 4 Grant or award Principal Accounting Officer acquired 11,850 shares (grant or award)
  13. 4 Grant or award Chief Medical Officer acquired 36,000 shares (grant or award)
  14. 4 Grant or award Chief Operating Officer acquired 30,000 shares (grant or award)
  15. 4 Grant or award President & CEO acquired 128,000 shares (grant or award)
  16. 4 Grant or award Chief Scientific Officer acquired 36,000 shares (grant or award)
  17. 4 Derivatives Options or other derivatives
  18. 3 Insider Initial Statement of Ownership
  19. 4 Open-market sale 10% owner sold 157,895 shares at an average $9.44 ($1,491,041)
  20. 4 Open-market sale 10% owner sold 1,132,566 shares at $6.53 ($7,395,203)

Page 3 of 9 · 171 filings